Researchers identified 1924 recurrent nephrolithiasis events among 14,456 weighted patients who used an SGLT-2 inhibitor compared with 853 events among the 5877 patients who used a GLP-1 RA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback